InnoPCV / Innovac Therapeutics - LARVOL DELTA

A Phase Ia Study to Assess the Safety, Tolerability and Immunogenicity of a personalized cancer vaccine (InnoPCV/INV002) in Patients with Advanced Solid Tumors (SITC 2025) - "Eligible patients received tislelizumab (200 mg, IV Q3W) or sintilimab (200 mg, IV Q3W) for a lead-in period of one to three cycles. Combining ex vivo and in vitro expansion ELISpot results, showed 80-100% response rates to peptide pools (n=5 pools) corresponding to the vaccine neoantigens. These responses were observed despite the dysfunctional immune status of the patients' CD8+ T cells which contained very low frequencies of naïve cells (Median: 7.1%, n=5) and a preponderance of T effector-memory cells (Median: 76%, n=5).Conclusions InnoPCV was well tolerated at all dose levels and induced neoantigen-specific T cells to multiple neoantigens encoded in the vaccine after 4 or less immunizations at the 0.3 and 1 mg doses.Acknowledgements We'd like to thank the patients who participated in this Phase 1a trial.Trial Registration NCT06497010Ethics Approval Ethical Approval: The study was approved by Affiliated Hospital of Guizhou Medical University's Ethics..."

Clinical • IO biomarker • Metastases • P1 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD8